ONYX-II: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Coadministered with Ribavirin in Asian Adults with Genotype 1b Chronic Hepatitis C Virus Infection and Compensated Cirrhosis

被引：0
|
作者：
Wei, Lai [1 ]
Wang, Qui-Qiang [2 ]
Luo, Yan [3 ]
Chu, Chi-Jen [4 ]
Paik, Seung Woon [5 ]
Hou, Jinlin [6 ]
Cheng, Jun [7 ]
Xie, Qing [8 ]
Duan, Zhongping [9 ]
Kao, Jia-Horng [10 ]
Fu, Bo [3 ]
Mobashery, Niloufar [3 ]
Heo, Jeong [11 ,12 ]
机构：
[1] Peking Univ, Peoples Hosp, Beijing, Peoples R China
[2] Peking Univ, Hosp 1, Beijing, Peoples R China
[3] AbbVie Inc, N Chicago, IL USA
[4] Taipei Vet Gen Hosp, Taipei, Taiwan
[5] Samsung Med Ctr, Seoul, South Korea
[6] Southern Med Univ, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China
[7] Capital Med Univ, Beijing Di Tan Hosp, Beijing, Peoples R China
[8] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Shanghai, Peoples R China
[9] Capital Med Univ, Beijing Youan Hosp, Beijing, Peoples R China
[10] Natl Taiwan Univ Hosp, Zhongzheng Dist, Taiwan
[11] Pusan Natl Univ, Coll Med, Dept Internal Med, Busan, South Korea
[12] Pusan Natl Univ Hosp, Med Res Inst, Busan, South Korea
来源：
HEPATOLOGY | 2016年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
875
引用
收藏
页码：434A / 434A
页数：1
相关论文
共 50 条
  • [21] SAFETY OF OMBITASVIR/PARITAPREVIR/RITONAVIR plus DASABUVIR IN CHRONIC HEPATITIS C PATIENTS WITH HCV GENOTYPE 1 INFECTION
    Tatara, Tomasz
    Dabrowska-Bender, Marta
    Duda-Zalewska, Aneta
    Staniszewska, Anna
    ACTA POLONIAE PHARMACEUTICA, 2019, 76 (04): : 613 - 619
  • [22] Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection
    Johnson, Scott J.
    Parise, Helene
    Virabhak, Suchin
    Filipovic, Ivana
    Samp, Jennifer C.
    Misurski, Derek
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (10) : 983 - 994
  • [23] Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection
    Smith, Michael A.
    Lim, Alice
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 6083 - 6094
  • [24] EFFICACY AND SAFETY OF OMBITASVIR, PARITAPREVIR/RITONAVIR, AND DASABUVIR WITHOUT RIBAVIRIN IN PATIENTS WITH HCV GENOTYPE 1B WITH OR WITHOUT COMPENSATED CIRRHOSIS: POOLED ANALYSIS ACROSS 5 CLINICAL TRIALS
    Welzel, T. M.
    Isakov, V.
    Trinh, R.
    Streinu-Cercel, A.
    Dufour, J. -F.
    Marinho, R. T.
    Moreno, C.
    Liu, L.
    Xie, W.
    Tatsch, F.
    Shulman, N.
    Craxi, A.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S824 - S824
  • [25] Efficacy and Safety of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir Without Ribavirin in Patients with HCV Genotype 1b With or Without Compensated Cirrhosis: Pooled Analysis Across 5 Clinical Trials
    Welzel, Tania M.
    Isakov, Vasily
    Trinh, Roger N.
    Streinu-Cercel, Adrian
    Dufour, Jean-Francois
    Marinho, Rui T.
    Moreno, Christophe
    Liu, Li
    Xie, Wangang
    Tatsch, Fernando
    Shulman, Nancy S.
    Craxi, Antonio
    GASTROENTEROLOGY, 2016, 150 (04) : S1095 - S1095
  • [26] Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir Plus Ribavirin in Daily Practice Hepatitis C Virus Genotype 1-or 4-Infected Patients with Compensated Cirrhosis
    Petta, Salvatore
    Marzioni, Marco
    Russo, Pierluigi
    Aghemo, Alessio
    Alberti, Alfredo
    Ascione, Antonio
    Antinori, Andrea
    Bruno, Raffaele
    Bruno, Savino
    Chirianni, Antonio
    Gaeta, Giovanni B.
    Giannini, Edoardo G.
    Merli, Manuela
    Messina, Vincenzo
    Montilla, Simona
    Perno, Carlo F.
    Puoti, Massimo
    Raimondo, Giovanni
    Rendina, Maria
    Ceccherini-Silberstein, Francesca
    Villa, Erica
    Zignego, Anna Linda
    Pani, Luca
    Craxi, Antonio
    HEPATOLOGY, 2016, 64 : 448A - 448A
  • [27] Real-life data on the efficacy and safety of ombitasvir/paritaprevir//ritonavir plus dasabuvir plus ribavirin in the patients with genotype 1 chronic hepatitis C virus infection in Serbia
    Babic, Jasmina Simonovic
    Bojovic, Ksenija
    Fabri, Milotka
    Cvejic, Tatjana
    Svorcan, Petar
    Nozic, Darko
    Jovanovic, Maja
    Skrbic, Ranko
    Stojiljkovic, Milos P.
    Mijailovic, Zeljko
    VOJNOSANITETSKI PREGLED, 2019, 76 (05) : 531 - 536
  • [28] Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection
    Perello, C.
    Carrion, J. A.
    Ruiz-Antoran, B.
    Crespo, J.
    Turnes, J.
    Llaneras, J.
    Lens, S.
    Delgado, M.
    Garcia-Samaniego, J.
    Garcia-Paredes, F.
    Fernandez, I.
    Morillas, R. M.
    Rincon, D.
    Porres, J. C.
    Prieto, M.
    Lazaro Rios, M.
    Fernandez-Rodriguez, C.
    Hermo, J. A.
    Rodriguez, M.
    Herrero, J. I.
    Ruiz, P.
    Fernandez, J. R.
    Macias, M.
    Pascasio, J. M.
    Moreno, J. M.
    Serra, M. A.
    Arenas, J.
    Real, Y.
    Jorquera, F.
    Calleja, J. L.
    JOURNAL OF VIRAL HEPATITIS, 2017, 24 (03) : 226 - 237
  • [29] Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis
    Chun-Hsien Chen
    Chien-Hung Chen
    Chih-Lang Lin
    Chun-Yen Lin
    Tsung-Hui Hu
    Shui-Yi Tung
    Sen-Yung Hsieh
    Sheng-Nan Lu
    Rong-Nan Chien
    Chao-Hung Hung
    I-Shyan Sheen
    Scientific Reports, 9
  • [30] Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir Co-Administered with Ribavirin in Adults with Genotype 4 Chronic Hepatitis C Infection and Cirrhosis (AGATE-I)
    Asselah, Tarik
    Hassanein, Tarek I.
    Qaqish, Roula B.
    Feld, Jordan J.
    Hezode, Christophe
    Zeuzem, Stefan
    Ferenci, Peter
    Pilot-Matias, Tami
    Yu, Yao
    Redman, Rebecca
    Mobashery, Niloufar
    HEPATOLOGY, 2015, 62 : 563A - 564A
12345